Paraneoplastic hormones: Parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3471-3476

  Feng, Chen Chen ^a   Ding, Guan Xiong ^a   Song, Ning Hong ^b   Li, Xuan ^b   Wu, Zhong ^a   Jiang, Hao Wen ^a   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; Erythropoietin; Parathyroid hormone related protein; Vascular endothelial growth factor

Indexed keywords

CALCIUM; ERYTHROPOIETIN; PARATHYROID HORMONE RELATED PROTEIN; VASCULOTROPIN;

ARTICLE; CALCIUM BLOOD LEVEL; CANCER GRADING; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84891492208     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0924-7     Document Type: Article

References (36)

1. Motzer RJ et al. Renal cell carcinoma. Curr Probl Cancer. 1997;21:185-232.
2. Sourbier C et al. Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett. 2006;240:170-82.
3. Ding GX, Song NH, Feng CC, Xia GW, Jiang HW, Hua LX, et al. Is there an association between advanced stage of renal cell carcinoma and paraneoplastic syndrome? Med Princ Pract. 2012;21:370-4.
4. Minardi D, Lucarini G, Filosa A, et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol. 2008;21:447-55.
5. Ding GX, Feng CC, Song NH, Fang ZJ, Xia GW, Jiang HW, et al. Paraneoplastic symptoms: cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma. Urol Oncol. 2012. doi: 10.1016/j.urolonc.2012.03. 021.
6. Wiesener MS, Seyfarth M, Warecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99:3562-5.
7. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286:R977-88.
8. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9:18-30.
9. Esbrit P, Egido J. The emerging role of parathyroid hormone-related protein as a renal regulating factor. Nephrol Dial Transplant. 2000;15:1109-11.
10. Philbrick WM, Galbraith S, Wysolmerski JJ, Holt E, Orloff JJ, Yang KH, et al. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev. 1996;76:127-73.
11. Clemens TL, Cormier S, Eichinger A, Endlich K, Fiaschi-Taesch N, Fischer E, et al. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol. 2001;134:1113-36.
12. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002; p. 193-195.
13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
14. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003;170:1742-6.
15. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4:163-70.
16. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: a paradigm of lanthanic disease. Am J Clin Oncol. 1999;22:223-31.
17. Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL. deKernion JB, et al. Interleukin-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol Immunother. 1992;35:97-105.
18. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 1997;72:424-30.
19. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028-43.
20. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005;16:7-15.
21. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-60.
22. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
23. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
24. Kazal LA, Erslev AJ. Erythropoietin production in renal tumors. Ann Clin Sci. 1975;5:98-109.
25. Noguchi Y, Goto T, Yufu Y, Uike N, Hasegawa Y, Fukuda T, et al. Gene expression of erythropoietin in renal cell carcinoma. Intern Med. 1999;38:991-4.
26. Sakamoto S, Igarashi T, Osumi N, Imamoto T, Tobe T, Kamiya M, et al. Erythropoietin producing renal cell carcinoma in chronic hemodialysis patients: a report of two cases. Int J Urol. 2003;10:49-51.
27. Wiesener MS, Münchenhagen P, Gläser M, Sobottka BA, Kanup KX, Jozefowski K, et al. Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer. 2007;121:2434-42.
28. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647-57.
29. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res. 2005;11:20-7.
30. Gong K, Zhang N, Zhang Z, Na Y. Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther. 2006;5:582-5.
31. Scortegagna M, Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M, et al. HIF-2a regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005;105:3133-40.
32. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA. The HIF family member EPAS1/HIF-2a is required for normal hematopoiesis in mice. Blood. 2003;102:1634-40.
33. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 2006;15:6264-70.
34. Burton PB, Moniz C, Knight DE. Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. Biochem Biophys Res Commun. 1990;167:1134-8.
35. Gotoh A, Kitazawa S, Mizuno Y, Takenaka A, Arakawa S, Matsumoto O, et al. Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas. Cancer. 1993;71:2803-6.
36. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res. 2004;64:180-8.